Abstracts Archive - Page 624 of 2607 - ACR Meeting Abstracts

Abstract Number: 2121 • ACR Convergence 2022
Long-term Persistence of Second-line Biologics in Psoriatic Arthritis Patients with Prior TNF Inhibitor Exposure: A Nationwide Cohort Study from the French Health Insurance Database
Laura Pina Vegas¹, Emilie sbidian² and Pascal Claudepierre³, ¹Service de Rhumatologie, AP-HP, Hôpital Henri Mondor, Créteil, France, ²Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France, ³Paris Est Creteil University, Creteil, France
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are most often the first choice biologic treatment for patients with psoriatic arthritis (PsA). When their discontinuation is needed,…
Abstract Number: 2120 • ACR Convergence 2022
Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of 11 Phase 2/3 Clinical Studies in Psoriasis and Psoriatic Arthritis
Bruce Strober¹, Laura Coates², Jenny Yu³, Katelyn Rowland⁴, Evan Leibowitz⁴, Megan Miller⁵, Alexa Kollmeier⁶, Shu Li⁵, Yanli Wang⁵, Daphne Chan⁴, Soumya Chakravarty⁷, Ya-Wen Yang⁸, May Shawi⁸, Mark Lebwohl⁹ and Proton Rahman¹⁰, ¹Yale University, New Haven, CT; Central Connecticut Dermatology Research, Cromwell, CT, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Janssen Research & Development, LLC, Spring House, PA/San Diego, CA, USA, San Diego, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Research & Development, LLC, Spring House, PA/San Diego, Spring House, PA/San Diego, CA, ⁶Janssen-Cilag, Research & Development, LLC, San Diego, CA, ⁷Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁸Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁹Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰Memorial University, St. John's, NL, Canada
Background/Purpose: Guselkumab (GUS) is a fully human monoclonal antibody that selectively binds to the p19 subunit of interleukin-23, inhibiting its function. GUS has been shown…
Abstract Number: 2110 • ACR Convergence 2022
Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population
Laure Gossec¹, Mohamed Sharaf², Elke Theander³, Marlies Neuhold⁴, Paul Bergmans⁵, May Shawi⁶, Michelle Perate⁷, Christine Contré⁸ and Laura Coates⁹, ¹Sorbonne Université, Paris, France, ²Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, ³Formerly at Janssen Scientific Affairs, LLC, Solna, Sweden, ⁴Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁵Formerly at Janssen, Breda, Netherlands, ⁶Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, ⁹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: The Phase 3b COSMOS study (NCT03796858) demonstrated the efficacy and safety of guselkumab (GUS), an IL-23 p19 subunit inhibitor, in patients (pts) with psoriatic…
Abstract Number: 2129 • ACR Convergence 2022
Serum Extracellular Matrix Biomarkers Identify Response to Guselkumab in Psoriatic Arthritis; Post-hoc Analysis from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
Signe Holm Nielsen¹, Anne-Christine Bay-Jensen¹, Peder Frederiksen¹, Morten Karsdal¹, May Shawi², Soumya Chakravarty³, Alexa Kollmeier⁴, Warner Chen⁵ and Sheng Gao⁵, ¹Nordic Bioscience, Herlev, Denmark, ²Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ³Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁴Janssen-Cilag, Research & Development, LLC, San Diego, CA, ⁵Janssen Research and Development, LLC, Spring House, PA
Background/Purpose: Psoriatic arthritis (PsA) is a progressive, joint-degenerative inflammatory disease with cartilage destruction, bone erosion and growth, and synovitis. Extracellular matrix (ECM) remodeling is also…
Abstract Number: 2128 • ACR Convergence 2022
Consistent Long-Term Guselkumab Efficacy Across Psoriatic Arthritis Domains Irrespective of Baseline Patient Characteristics
Iain B McInnes¹, John Tesser², Elena Schiopu³, Joseph Merola⁴, Soumya Chakravarty⁵, Emmanouil Rampakakis⁶, Natalie Shiff⁷, Alexa Kollmeier⁸, Xie L Xu⁹, May Shawi¹⁰, Frederic Lavie¹¹, Paul Bird¹² and Philip J Mease¹³, ¹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ²Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ³Michigan Medicine Rheumatology Clinic – Taubman Center, Ann Arbor, MI, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁶McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁷Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA, ⁸Janssen-Cilag, Research & Development, LLC, San Diego, CA, ⁹Janssen Research & Development, LLC, San Diego, CA, USA, San Marcos, CA, ¹⁰Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ¹¹The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, Paris, France, ¹²University of New South Wales, Sydney, Australia, ¹³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: In the phase 3 DISCOVER (D)-1 and D-2 studies, guselkumab (GUS) significantly improved joint symptoms, skin disease, enthesitis, dactylitis, physical function, and quality of…
Abstract Number: 2127 • ACR Convergence 2022
Guselkumab Provides Continued Improvement in Key Domains of Psoriatic Arthritis Through 2 Years
Laura Coates¹, Laure Gossec², Christine Contré³, May Shawi⁴, Emmanouil Rampakakis⁵, Natalie Shiff⁶, Alexa Kollmeier⁷, Xie L Xu⁸, Peter Nash⁹, Philip J Mease¹⁰ and Philip Helliwell¹¹, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ²Sorbonne Université, Paris, France, ³Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, ⁴Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁵McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA, ⁷Janssen-Cilag, Research & Development, LLC, San Diego, CA, ⁸Janssen Research & Development, LLC, San Diego, CA, USA, San Marcos, CA, ⁹School of Medicine, Griffith University, Sunshine Coast, Australia, ¹⁰Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ¹¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Recent guidelines from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommend that psoriatic arthritis (PsA) therapy achieve lowest possible…
Abstract Number: 2122 • ACR Convergence 2022
Bimekizumab Treatment Improves Health-Related Quality of Life in Biologic DMARD-Naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Dafna Gladman¹, Lars Erik², Diamant Thaci³, Paolo Gisondi⁴, Laure Gossec⁵, M. Elaine Husni⁶, Alice Gottlieb⁷, Hiroaki Dobashi⁸, Barbara Ink⁹, Deepak Assudani⁹, Rajan Bajracharya⁹, Jason Coarse¹⁰, Jérémy Lambert¹¹ and William Tillett¹², ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ³Institute and Comprehensive Center for Inflammation Medicine, University Hospital of Lübeck, Lübeck, Germany, ⁴Dermatology and Venereology, Department of Medicine, Università di Verona, Verona, Italy, Verona, ⁵Sorbonne Université, Paris, France, ⁶Cleveland Clinic, Cleveland, OH, ⁷Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, NY, ⁸Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹¹UCB Pharma, Colombes, France, Irigny, France, ¹²Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: PsA imparts a substantial burden on patient health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition…
Abstract Number: 2131 • ACR Convergence 2022
Minimal Disease Activity Response Patterns in Bio-Naïve Patients Treated with Guselkumab: A Machine Learning Analysis
Alen Zabotti¹, Sarah Ohrndorf², William Tillett³, Marlies Neuhold⁴, Michel van Speybroeck⁵, Elke Theander⁶, Christine Contré⁷, Mohamed Sharaf⁸, May Shawi⁹, Michelle Perate¹⁰, Alexa Kollmeier¹¹ and Pascal Richette¹², ¹Department of Medical and Biological Sciences, Rheumatology Unit, University of Udine, Udine, Italy, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁴Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁵Janssen Pharmaceutica, Beerse, Belgium, ⁶Janssen Cilag, Lund, Sweden, ⁷Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, ⁸Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, ⁹Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ¹⁰Janssen Scientific Affairs, LLC, Horsham, PA, ¹¹Janssen-Cilag, Research & Development, LLC, San Diego, CA, ¹²Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19 subunit, demonstrated joint and skin efficacy in patients with active psoriatic arthritis (PsA) in the…
Abstract Number: 2135 • ACR Convergence 2022
Evaluation of Candidate Protein Biomarkers to Predict Treatment Response in Patients with Psoriatic Arthritis
James C Waddington¹, Ruoyi Zhou¹, Orla Coleman¹, Bruna Wundervald², Andrew Parnell³, Vinod Chandran⁴, Lara Fallon⁵, Douglass Chapman⁶, Remy Pollock⁷, Shibing Deng⁸, Oliver FitzGerald⁹, Stephen R Pennington¹⁰ and Philip J Mease¹¹, ¹Atturos, Dublin, Ireland, ²Atturos/Hamilton Institute, Maynooth University, Dublin, Ireland, ³Hamilton Institute, Maynooth University, Kildare, Ireland, ⁴Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁵Pfizer Inc, Montréal, QC, Canada, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Canada ULC, Kirkland QC, Canada, ⁸Pfizer Inc, Waterford, MI, ⁹Conway Institute, University College Dublin, Dublin, Ireland, ¹⁰Atturos/Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ¹¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA.1,2 Using two mass spectrometry (MS)-based proteomic approaches (targeted multiple reaction monitoring [MRM]…
Abstract Number: 2132 • ACR Convergence 2022
Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor: As Assessed by Laboratory Parameters – Results from a Phase 2 Trial in Psoriatic Arthritis and 2 Phase 3 Trials in Psoriasis
Roy Fleischmann¹, Diamant Thaci², Melinda Gooderham³, Bruce Strober⁴, Neil J. Korman⁵, Subhashis Banerjee⁶, Tom Lehman⁶, Miroslawa Nowak⁶, Antoine Sreih⁷, Akimichi Morita⁸ and Philip J Mease⁹, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Institute and Comprehensive Center for Inflammation Medicine, University Hospital of Lübeck, Lübeck, Germany, ³SKiN Centre for Dermatology, Queen’s University, Probity Medical Research, Peterborough, Canada, ⁴Yale University, New Haven, CT; Central Connecticut Dermatology Research, Cromwell, CT, ⁵Case Western Reserve University and University Hospitals, Cleveland, OH, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Philadelphia, PA, ⁸Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Deucravacitinib (DEUC) is a novel, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action distinct from Janus kinase (JAK)…
Abstract Number: 2136 • ACR Convergence 2022
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis: Achievement of Minimal Disease Activity and Its Components
Arthur Kavanaugh¹, Laura Coates², Joseph Merola³, Philip J Mease⁴, Miroslawa Nowak⁵, Subhashis Banerjee⁵, Lauren Hippeli⁵ and Tom Lehman⁵, ¹University of California San Diego, La Jolla, CA, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁵Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase in the Janus kinase (JAK) family that mediates the signaling of multiple cytokines, including those central…
Abstract Number: 2048 • ACR Convergence 2022
Serology Driven Pulmonary Phenotype Characterization of Sjögren Syndrome-associated Interstitial Lung Disease: A Monocentric Cohort Study
Gaetano La Rocca¹, Francesco Ferro², Giovanni Fulvio³, Silvia Fonzetti⁴, Inmaculada Concepción Navarro García⁵, Elena Elefante⁶, Chiara Romei⁷, Marta Mosca⁶ and Chiara Baldini³, ¹University of Pisa, Rheumatology Unit, Palermo, Palermo, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ³University of Pisa, Pisa, Pisa, Italy, ⁴Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, ⁵Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁶University of Pisa, Pisa, Italy, ⁷University of Pisa, Rheumatology Unit, Pisa, Italy
Background/Purpose: Interstitial lung disease (ILD) is a relatively frequent manifestation of Sjögren's Syndrome (pSS), potentially presenting with a wide spectrum of clinical-radiological characteristics. Anti-Ro52 autoantibodies…
Abstract Number: 1794 • ACR Convergence 2022
Characteristics of Patients with Repeat Visits for Acute Gout at a University Hospital Emergency Department
David Lim¹, Manushi Aggarwal¹ and Marven Cabling², ¹Loma Linda University Health, Redlands, CA, ²Loma Linda University, REDLANDS, CA
Background/Purpose: Gout is the most common inflammatory arthritis in adults that results in high disease burden and health care utilization. The objective of the study…
Abstract Number: 2138 • ACR Convergence 2022
Real-world Persistence and Treatment Patterns in Psoriatic Arthritis Patients Treated with Anti-IL17 Therapy
BEATRIZ E. JOVEN¹, Concepción Fito Manteca², Enrique Rubio³, Enrique Raya Álvarez⁴, Alba Pérez⁵, Raquel Hernández⁶, Sara Manrique Arija⁷, Mercedes Núñez⁸, Silvia Díaz⁸, Luis Trancho⁸, Sebastian Moyano⁸, Alessandra Lacetera⁹, Noelia Alfaro-Oliver⁹ and Rosario Garcia-Vicuña¹⁰, ¹Hospital Universitario 12 de Octubre, Madrid, Spain, ²Hospitalario de Navarra, Pamplona, Spain, ³Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁴Hospital Universitario San Cecilio, Granada, Spain, ⁵Hospital Puerta del Mar, Cádiz, Spain, ⁶Virgen de Valme University Hospital, Sevilla, Spain, ⁷Hospital Regional Universitario Málaga, Málaga, Spain, ⁸Lilly, Alcobendas, Spain, ⁹OXON Epidemiology, Madrid, Spain, ¹⁰Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain
Background/Purpose: Interleukin-17A inhibitors (anti-IL17) have provided an additional treatment option in the management of the psoriatic arthritis (PsA). This study aims to describe the patient…
Abstract Number: 2137 • ACR Convergence 2022
Impact of Patient Characteristics, Including Sex, on the Efficacy of Upadacitinib Compared with Adalimumab in Patients with Psoriatic Arthritis
Lihi Eder¹, Laura Coates², Peter Nash³, Uta Kiltz⁴, Ennio Lubrano⁵, Erin McDearmon-Blondell⁶, Tianming Gao⁷ and Alexis Ogdie⁸, ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³School of Medicine, Griffith University, Brisbane, Australia, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ‘‘Vincenzo Tiberio’’, Università degli Studi del Molise, Campobasso, Italy, ⁶AbbVie, Inc., Mettawa, IL, ⁷AbbVie, Inc., North Chicago, IL, ⁸Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Evidence suggests that response to treatment in PsA may vary with patient (pt) characteristics, such as sex.1 This post hoc analysis of the Phase…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].